Alembic shines on receiving USFDA approval for Leflunomide drug

24 Nov 2011 Evaluate

Alembic is currently trading at Rs. 16.10, up by 0.30 points or 1.90% from its previous closing of Rs. 15.80 on the BSE.

The scrip opened at Rs. 16.00 and has touched a high and low of Rs. 16.50 and Rs. 15.80 respectively. So far 4,148 shares were traded on the counter.

The BSE group 'B' stock of face value Rs. 2 has touched a 52 week high of Rs. 39.80 on 11-Apr-2011 and a 52 week low of Rs. 15.70 on 23-Nov-2011.

Last one week high and low of the scrip stood at Rs. 17.25 and Rs. 15.70 respectively. The current market cap of the company is Rs. 215.00 crore.

The promoters holding in the company stood at 63.48% while Institutions and Non-Institutions held 10.12% and 26.40% respectively.

Alembic has got an approval of US Food and Drug Administration (USFDA) for the generic version of arthritis drug Leflunomide. The approval is for 10 mg and 20 mg strengths of Leflunomide tablets.

Leflunomide is prescribed in active, moderate, and severe rheumatoid arthritis and psoriatic arthritis and is sold by French pharmaceutical major Sanofi-Aventis under the brand name Arava.

Alembic is a leading pharmaceutical company in India. The company is vertically integrated with the ability to develop, manufacture and market pharmaceutical products, pharmaceutical substances and Intermediates.

Alembic Share Price

123.45 -1.75 (-1.40%)
21-Nov-2024 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1777.65
Dr. Reddys Lab 1194.55
Cipla 1465.65
Lupin 2043.30
Zydus Lifesciences 944.25
View more..
© 2024 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.